340 related articles for article (PubMed ID: 27618321)
1. Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review.
Katabathina VS; Menias CO; Tammisetti VS; Lubner MG; Kielar A; Shaaban A; Mansour J; Surabhi VR; Hara AK
Radiographics; 2016; 36(5):1390-407. PubMed ID: 27618321
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
Gutierrez-Dalmau A; Campistol JM
Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
[TBL] [Abstract][Full Text] [Related]
3. Posttransplant Malignancy.
Rossi AP; Klein CL
Surg Clin North Am; 2019 Feb; 99(1):49-64. PubMed ID: 30471741
[TBL] [Abstract][Full Text] [Related]
4. De Novo Malignancies After Transplantation: Risk and Surveillance Strategies.
Doycheva I; Amer S; Watt KD
Med Clin North Am; 2016 May; 100(3):551-67. PubMed ID: 27095645
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors.
Piselli P; Verdirosi D; Cimaglia C; Busnach G; Fratino L; Ettorre GM; De Paoli P; Citterio F; Serraino D
Best Pract Res Clin Obstet Gynaecol; 2014 Nov; 28(8):1251-65. PubMed ID: 25209964
[TBL] [Abstract][Full Text] [Related]
6. Post-renal transplant malignancies: Opportunities for prevention and early screening.
Turshudzhyan A
Cancer Treat Res Commun; 2021; 26():100283. PubMed ID: 33338850
[TBL] [Abstract][Full Text] [Related]
7. New concepts and best practices for management of pre- and post-transplantation cancer.
Campistol JM; Cuervas-Mons V; Manito N; Almenar L; Arias M; Casafont F; Del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Román A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2012 Oct; 26(4):261-79. PubMed ID: 22902168
[TBL] [Abstract][Full Text] [Related]
8. De novo malignancies after liver transplantation: a major cause of late death.
Fung JJ; Jain A; Kwak EJ; Kusne S; Dvorchik I; Eghtesad B
Liver Transpl; 2001 Nov; 7(11 Suppl 1):S109-18. PubMed ID: 11689783
[TBL] [Abstract][Full Text] [Related]
9. Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation.
Dantal J; Campone M
Transplantation; 2016 Dec; 100(12):2569-2583. PubMed ID: 27861286
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.
Krisl JC; Doan VP
Am J Transplant; 2017 Aug; 17(8):1974-1991. PubMed ID: 28394486
[TBL] [Abstract][Full Text] [Related]
11. Complications of Immunosuppressive Therapy in Solid Organ Transplantation.
Katabathina V; Menias CO; Pickhardt P; Lubner M; Prasad SR
Radiol Clin North Am; 2016 Mar; 54(2):303-19. PubMed ID: 26896226
[TBL] [Abstract][Full Text] [Related]
12. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
13. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment.
Stockfleth E; Ulrich C; Meyer T; Christophers E
Recent Results Cancer Res; 2002; 160():251-8. PubMed ID: 12079221
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
Bhat M; Mara K; Dierkhising R; Watt KDS
Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
[TBL] [Abstract][Full Text] [Related]
15. Malignancy in pediatric transplant recipients.
Buell JF; Gross TG; Thomas MJ; Neff G; Muthiah C; Alloway R; Ryckman FC; Tiao GM; Woodle ES
Semin Pediatr Surg; 2006 Aug; 15(3):179-87. PubMed ID: 16818139
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous Malignancies in Pediatric Solid Organ Transplant Recipients.
Fogel AL; Miyar M; Teng JM
Pediatr Dermatol; 2016 Nov; 33(6):585-593. PubMed ID: 27470071
[TBL] [Abstract][Full Text] [Related]
17. Management of solid tumours in organ-transplant recipients.
Ajithkumar TV; Parkinson CA; Butler A; Hatcher HM
Lancet Oncol; 2007 Oct; 8(10):921-32. PubMed ID: 17913661
[TBL] [Abstract][Full Text] [Related]
18. De novo malignancies after intestinal and multivisceral transplantation.
Abu-Elmagd KM; Zak M; Stamos JM; Bond GJ; Jain A; Youk AO; Ezzelarab M; Costa G; Wu T; Nalesnik MA; Mazariegos GV; Sindhi RK; Marcos A; Demetris AJ; Fung JJ; Reyes JD
Transplantation; 2004 Jun; 77(11):1719-25. PubMed ID: 15201672
[TBL] [Abstract][Full Text] [Related]
19. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant malignancy.
Trofe J; Beebe TM; Buell JF; Hanaway MJ; First MR; Alloway RR; Gross TG; Woodle ES
Prog Transplant; 2004 Sep; 14(3):193-200. PubMed ID: 15495778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
